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Allopurinol Desensitization: A Fast or Slow Protocol?
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Desensibilización.
The main indication for treatment with allopurinol 
is hyperuricemia in patients with gout and uric acid 
nephrolithiasis. It is particularly indicated in patients with 
chronic renal insufficiency (CRI), as this renders uricosuric 
drugs ineffective.
Adverse reactions are estimated to affect 2% of patients 
treated with allopurinol [1], and range from mild rash (in the 
majority of cases) to severe reactions such as Stevens Johnson 
syndrome, toxic epidermal necrolysis [2], and allopurinol 
hypersensitivity syndrome (approximately 0.4% of cases) [3].
Desensitization attempts have been reported, several with 
successful outcomes [4-9]. Patients are eligible for allopurinol 
desensitization when they have mild reactions or when no 
alternative treatments are available, since in many countries, 
such as Portugal, substitute drugs are not available.
We describe our experience with 2 allopurinol 
desensitization protocols in an immunoallergology department. 
We performed a chart review of all patients who underwent 
desensitization with allopurinol between 2003 and 2013. 
Nineteen patients underwent 21 desensitizations with either 
a slow protocol (starting with a 10-μg dose and ending with a 
100- or 300-mg dose after 16 days) or a fast protocol (starting 
with 50 μg and ending with 100 mg after 5 days, although if 
necessary, this can be later increased to 300 mg). 
Demographic characteristics, indication for treatment with 
allopurinol, type and timing of reaction, number of previous 
reactions, comorbidities, and desensitization protocol and 
outcome were recorded. Patients were contacted by phone to 
confirm current drug tolerance.
The 19 patients had a mean (SD) age of 64.1 (14) years 
and a median age of 66 years (range, 43-83 years); 63% were 
men. All the patients met the criteria for treatment: 14 had 
gout, 2 had kidney stones, and 3 had both. 
Six patients (32%) had absolute indication for treatment 
with allopurinol due to CRI. The majority of patients (68%) 
had experienced just 1 prior reaction, 4 had experienced 2 
reactions, and 2 had experienced 3 or more reactions. 
Nine patients had experienced maculopapular rash, 3 
urticaria, 2 angioedema, 2 generalized erythema and pruritus, 
and 2 pruritus without cutaneous lesions. One man had 
experienced edema and erythema on the penis. The reactions 
had been immediate in 5 patients and delayed in 14.
Two patients were desensitized twice. Patient #10 
first underwent a slow protocol, which she tolerated. She 
subsequently stopped taking allopurinol due to maintenance 
of normal uric acid levels, but 1 year later the hyperuricemia 
returned. Full-dose intake of allopurinol was attempted but was 
unsuccessful. The patient underwent desensitization again, but 
this time with a fast protocol. The result was successful. The 
other patient (#16) underwent both the fast and slow protocols, 
but failed to achieve tolerance.
Overall, 11 desensitizations (52%) were successful and 
resulted in good control of uric acid levels and thus of the 
underlying symptoms (Table). Eight patients are currently 
taking 100 mg of allopurinol while 3 are taking 300 mg 
daily. The 16-day protocol had a 64% success rate (7/11 
desensitizations), while the 5-day protocol had a 40% success 
rate (4/10 desensitizations). There were thus 10 unsuccessful 
desensitizations. In 9 of the cases, the patients developed a 
reaction during the protocol and in the 10th case, the patient’s 
symptoms resumed 1 week after completion of the protocol. 
Of the 13 patients who had reported only 1 prior reaction, 54% 
were unable to tolerate the desensitization, while in the group 
of 6 patients who had had 2 or more previous reactions, 33% 
were unable to tolerate it.
While the pathological mechanism underlying allopurinol 
hypersensitivity is not fully understood, CRI has been 
suggested as a risk factor for adverse reactions [10], probably 
due to underexcretion and accumulation of allopurinol and its 
metabolite oxypurinol [5]. Because there are no alternatives 
to allopurinol in many countries, numerous desensitization 
procedures have been studied and developed over the past 30 
years. In our series, half of the patients with CRI and 54% of 
those without tolerated desensitization. We cannot therefore 
draw any conclusions as to the relevance of CRI in this context. 
Most of the literature on allopurinol desensitization 
refers to slow protocols, which are based on very gradual 
dose increases, generally over a period of 28 days [4,5,7,9]. 
Fast desensitization protocols are less common [8]. In our 
department, we started out by using only a slow protocol, 
although it was shorter than most of the protocols previously 
reported. We now, however, mostly use the faster 5-day 
protocol [8], as it is more convenient for both patients and 
the department. The overall success rate of desensitization in 
our department (52%) is lower than rates reported in larger 
series (66%-78%) [5,6,9], although these series only studied 
1 type of protocol. Our results show that the 5-day protocol 
was not tolerated in 60% of cases; 5 of the 6 patients in whom 
the protocol failed did not complete desensitization due to 
symptoms, which in some cases were more severe than the 
initial reaction, and 1 started showing symptoms again a 
week after completion of the protocol. The slow protocol was 
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tolerated in 64% of cases, which is more similar to previously 
reported results [5,6,9]. 
Confirmation of allopurinol hypersensitivity requires 
a thorough clinical history and challenge tests, since there 
are no other validated tests. In our series, 68% of patients 
reported only 1 previous episode of a suspected reaction. Due 
to the urgent need for resuming treatment with allopurinol, a 
clinical decision was made to skip the challenge and proceed 
to desensitization. The procedure was not tolerated in over half 
of these patients (54%), confirming hypersensitivity. In the 
remaining 6 patients who tolerated desensitization a diagnosis 
was not confirmed, as at the time, the benefits of desensitization 
outweighed the need for confirmation.
In conclusion, the risks and benefits of allopurinol 
desensitization must be weighed up in each patient. The fact 
that the slow protocol was more frequently tolerated than the 
fast one raises the question as to whether the fast protocol 
should be retained in view of its lower success rates. As 
previously mentioned, the 16-day protocol we use is shorter 
than most of the slow protocols described in the literature, 
rendering it more convenient for patients, while still producing 
similar results to those reported in the largest case series 
reported to date [9].
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Table. Type of Reactions and Desensitization Outcomes
Patient Initial Reaction  Protocol Breakthrough Reactions  Current 
  Type Timing  Characteristics Timing Tolerance 
1 Facial pruritus Delayed 16 days n/a n/a Yes
2 Generalized rash Delayed 16 days n/a n/a Yes
3 Generalized rash Delayed 16 days Generalized maculopapular rash and  delayed No 
    bullous exanthema on the legs 
4 Urticaria Immediate 16 days n/a n/a Yes
5 Lip angioedema Immediate 16 days Lip angioedema Immediate No
6 Urticaria Immediate 16 days Generalized maculopapular rash Delayed No
7 Urticaria Immediate 16 days n/a n/a Yes
8 Generalized rash Delayed 16 days n/a n/a Yes
9 Angioedema Immediate 16 days n/a n/a Yes
10 Generalized pruritus Delayed Both n/a n/a Yes
11 Generalized rash Delayed 5 days n/a n/a yes
12 Generalized erythema and pruritus Delayed 5 days n/a n/a Yes
13 Generalized erythema and pruritus Delayed 5 days Generalized erythema and pruritus Delayed No
14 Edema and erythema of the penis Delayed 5 days Generalized rash Delayed No
15 Generalized rash and pruritus Delayed 5 days Generalized dermatitis, eyelid edema Delayed No
16 Generalized rash, hand pruritus Delayed Both Generalized erythema and pruritus Delayed No
17 Generalized rash and erythema,  Delayed 5 days n/a n/a Yes 
 face angioedema 
18 Generalized rash Delayed 5 days Generalized pruritus, bronchospasm Delayed No
19 Generalized dermatitis Delayed 5 days Generalized dermatitis Delayed No
Abbreviation: n/a, not applicable. 
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Heparin and low-molecular-weight heparin are widely 
used anticoagulants in the prophylaxis and treatment of 
thromboembolic diseases and in hemodialysis. Although 
heparins are very common, allergic reactions due to substances 
in this group are rare. The most common reactions involve 
cell-mediated hypersensitivity with clinical manifestations 
of erythematous plaques and occasionally maculopapular 
exanthemas. The most dangerous hypersensitivity reaction is 
heparin-induced thrombocytopenia, a type II IgG antibody–
mediated reaction. Heparin-induced thrombocytopenia II and 
anaphylaxis are infrequent [1-2]. Anaphylaxis is a serious, 
life-threatening generalized or systemic hypersensitivity 
reaction [3]. Early diagnosis of potentially life-threatening 
adverse events and identification of alternatives is therefore 
clinically important. 
In some anticoagulant-associated hypersensitivity 
reactions detailed allergologic investigation may help 
to identify safe treatment alternatives. In suspected 
IgE-mediated hypersensitivity, serial serum tryptase 
measurements during an acute episode, skin tests including 
prick, intradermal, and patch tests, as well as challenge tests 
are the most reliable diagnostic tools for heparin- or hirudin-
induced anaphylaxis [1].
We present the case of a 51-year-old man with a history 
of uncontrolled polycystic disease who developed chronic 
kidney disease requiring hemodialysis. His usual treatment 
involved taking multivitamins, folic acid, omeprazole, and 
calcium. 
Five minutes after initiating the fifth hemodialysis 
session, the patient presented facial erythema, dyspnea, and 
chest tightness. Tachycardia at 120 bpm, hypotension, and 
desaturation (PO2 of 85%) were observed. A few minutes later 
he began with chills, shivering, and an increase in temperature 
from 36.6ºC to 37.8ºC. There were no other associated skin 
lesions or thromboembolic effects; the only drug used during 
this procedure was intravenous enoxaparin. The patient 
required acute treatment with fluid, oxygen, corticosteroid, 
and intravenous antihistamine. The next hemodialysis was 
well tolerated until enoxaparin was administered at the end 
of the session, with the patient presenting identical symptoms 
and responding to treatment as before.
Infection as a possible cause was ruled out. No remarkable 
analytical findings were observed during either episode. 
Serial determination of serum tryptase after the first episode 
  Manuscript received January 27, 2014; accepted for publication, 
September 4, 2014. 
Joana Bruno Soares
Hospital Santa Maria, Centro Hospitalar Lisboa Norte
Av. Prof. Egas Moniz
1649-035 Lisbon
Portugal
E-mail: joanabsoares@gmail.com
297
5.  Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to 
allopurinol in patients with gout and cutaneous reactions. Am 
J Med. 1992 Sep;93(3):299–302. 
6.  Silva SL, Santos AS, Pregal AL, Pedro E, Ferreira MB, Carlos AP, 
Barbosa MP. Allopurinol: experience in desensitization. Rev 
Port Imunoalergologia 2004; 12:390-9.
7.  Kelso JM, Keating RM. Successful desensitization for treatment 
of a fixed drug eruption to allopurinol. J Allergy Clin Immunol. 
1996 May;97(5):1171–2. 
8.  Nitti F, Fumagalli M, Incorvaia C. Rush desensitization to 
allopurynol. Allergy. 2003 Jul;58(7):690. 
9.  Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of 
desensitization to allopurinol following cutaneous reactions. 
Arthritis Rheum. 2001;44(1):231–8. 
10.  Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-
Vargas R. Relation between adverse events associated with 
allopurinol and renal function in patients with gout. Ann 
Rheum Dis. 2001;60(10):981–3.
Practitioner's Corner
J Investig Allergol Clin Immunol 2015; Vol. 25(4): 295-315 © 2015 Esmon Publicidad
and prior to and after the administration of enoxaparin in 
the second episode was measured. The results are shown 
in the Table. An allergy study was performed using skin 
prick, intradermal, and patch tests with heparin-sodium, 
bemiparin, nadroparin, dalteparin, enoxaparin, fondaparinux, 
and latex. A basophil activation test (BAT) with enoxaparin 
and fondaparinux was also performed using a previously 
described technique [4]. After obtaining informed consent, 
a challenge test was performed with fondaparinux to assess 
its viability as an alternative anticoagulant. No variations in 
tryptase levels were observed. Cutaneous tests and BAT were 
negative. Subcutaneous and intravenous fondaparinux was 
tolerated at full doses.
There are few reports in the literature of adverse reactions 
to low-molecular-weight heparins. Anders and Trautmann [7] 
also described a case of anaphylaxis due to enoxaparin. In 
their patient, prick tests to enoxaparin, fondaparinux, heparin-
sodium, dalteparin, and danaparoid were positive; they also 
used BAT and the result was negative as in our case. BAT was 
proposed as a complementary method for the in vitro diagnosis 
of heparin allergy by Caballero et al [8] after obtaining positive 
results with heparin-sodium and enoxaparin in patients with 
allergic reactions to heparins.
Another case of anaphylaxis due to enoxaparin was 
described by MacLaughlin et al [9], but the limitation of that 
case report was that skin tests (prick or intradermal) and BAT 
were not performed to confirm the diagnosis of an allergic 
reaction.
In our case there was a clear relationship between the 
anaphylactic reaction and the administration of enoxaparin at 
different times of the hemodialysis, excluding therefore the 
involvement of other components used in the hemodialysis 
process, such as dialysis membranes or disinfectants. 
Hemodialysis with the same components was well tolerated 
after changing the anticoagulant to fondaparinux.
Mast cells and basophils are considered critical components 
of an allergic response because they express the high-affinity 
IgE receptor and secrete mediators known to be responsible 
for the symptoms and pathology of allergy diseases. Serum 
tryptase concentration is the best biomarker to assess mast 
cell activation and is considered a specific marker of mast 
cell degranulation. This enzyme remains elevated hours after 
systemic allergic reactions [3]. Berkum et al [6] confirmed the 
diagnosis of heparin allergy by skin tests and elevated serum 
tryptase levels and deduced allergy to enoxaparin through 
positive skin tests. In our case we did not observe any variation 
in serum tryptase levels.
In the studies summarized above, skin testing was used to 
reach a diagnosis of anaphylaxis due to an allergic reaction. 
Serum tryptase elevation and basophil activation involve the 
same mechanism. However, the diagnostic value of cutaneous 
tests with heparins seems to be low [5]. BAT results can 
sometimes be suggestive of an IgE-mediated reaction, but the 
test is not widely available [4,8].
Our patient tolerated fondaparinux as an alternative 
treatment, as previously reported in a case of enoxaparin-
induced anaphylaxis [10]. There have been descriptions of 
non-IgE-mediated adverse reactions to heparins, such as 
heparin-induced thrombocytopenia, and in such cases, there 
may be broad cross-reactivity among heparins. However, 
hirudins, danaparoid, and fondaparinux can all be used as 
valid alternatives [2].
In conclusion, we have presented a patient who developed 
an immediate adverse reaction to enoxaparin in which an IgE 
mechanism could not be demonstrated with cutaneous or in 
vitro tests and fondaparinux proved to be a safe alternative.
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Table. Results of Serial Serum Tryptase Measurements (mcg/L)
 Prehemodialysis 2 Hours 6 Hours
First episode - 6.65 7.48
Second episode 7.55 8.16 7.51
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Common variable immunodeficiency (CVID) and selective 
IgA deficiency (SIgAD) constitute 2 important predominantly 
antibody deficiencies. Patients with CVID usually have 
reduced levels of at least 2 immunoglobulin isotypes, 
predisposing them to a number of infections, while patients 
with SIgAD simply have reduced levels of serum IgA and 
may be asymptomatic [1-4]. Some patients with SIgAD also 
have IgG subclass deficiency and may occasionally progress 
to CVID [5]. RAD50, which has a major role in several steps 
of DNA mismatch repair (MMR), seems to be associated with 
SIgAD and CVID [6]. The present study was performed to 
evaluate the association between RAD50 and susceptibility to 
SIgAD or CVID in an Iranian population.
Thirty-nine patients with CVID (21 males and 18 females) 
and 19 patients with SIgAD (10 males and 9 females) from 
leading referral hospitals in Tehran, Iran, were enrolled in this 
study. All the patients were diagnosed according to the standard 
criteria, defined by the International Union of Immunological 
Societies: Primary Immunodeficiency Diseases Classification 
Committee [7]. Thirty-four healthy individuals (20 males and 
14 females) were included as the control group. Informed 
consent was obtained from all participants before sampling, 
and the study was approved by the ethics committee of Tehran 
University of Medical Sciences.
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In order to determine allele frequencies for the RAD50 
single-nucleotide polymorphism (SNP) Rs2237060, 5 mL of peripheral 
blood was collected from all the participants in EDTA-treated tubes and 
genomic DNA was extracted from peripheral blood leucocytes using 
the proteinase K phenol-chloroform extraction method. Real-time PCR 
allelic discrimination TaqMan genotyping assays (Applied Biosystems) 
and the ABI 7300 Real-Time PCR system were used to determine allele 
frequencies. Reactions were processed following standard protocols 
established by Applied Biosystems.
The frequencies of all genotypes were compared between patient 
and control groups (Table). Allele frequencies for the previously 
reported Rs2237060 SNP were similar in patients and healthy controls. 
Although the AA genotype was more common in patients with CVID 
and SIgAD compared with controls, the difference was not significant. 
On comparing patients with CVID and patients with SIgAD, no 
significant differences in allele frequencies were observed.
This study analyzed the contribution of the RAD50 SNP Rs2237060 
to susceptibility to SIgAD and CVID. An association between this SNP 
and SIgAD and CVID was recently reported in Swedish patients with 
these 2 diseases [6]. We did not, however, observe this association in our 
study. In another recent study by our group [8], we also failed to observe 
another association reported in the Swedish study, namely an association 
between an intronic SNP of the AICDA gene and SIgAD/CVID [6].
The reason for the discordance between our results and those of 
the Swedish study is probably related to the heterogeneous nature of 
CVID and SIgAD. Although RAD50 might be a risk factor for CVID 
or SIgAD in a subset of patients in the Swedish study, this subset may 
constitute a small percentage of our study population or may even have 
been absent. Another possibility is high variability in allele frequencies 
between different ethnic groups.
Normal quantities of IgA-bearing B-cell precursors in the majority 
of patients with SIgAD and normal numbers of IgA-, IgG-, and IgM-
bearing B cell precursors in the majority of patients with CVID provide 
evidence on normal class-switch recombination (CSR) in CVID and 
SIgAD [9,10]. It has been suggested that in most patients, the disease 
results from blockage in differentiation of mature B cells into plasma 
cells [9,10]. However, RAD50 SNPs may be involved in a subset of 
patients with decreased levels of somatic hypermutation (SHM) and 
CSR. However, there are still some controversies in this regard, and the 
genetic defect involved in CVID and SIgAD has not yet been identified.
In conclusion, the results of our study did not confirm the 
previously reported association between the RAD50 SNP Rs2237060 
and the development of either CVID or SIgAD. Although we did 
not find any association between RAD50 and CVID or IgAD, a 
growing body of evidence shows the importance of DNA MMR in the 
pathogenesis of CVID and SIgAD in a subtype of patients. Elucidating 
the exact role of proteins involved in MMR, CSR, and SHM in the 
pathogenesis of these diseases may help us to classify patients into 
subgroups, paving the way for the treatment of patients with certain 
subclasses of disease [10]. Therefore, despite our negative result, future 
studies should continue to investigate associations between CVID and 
SIgAD and variations of genes involved not only in MMR, but also in 
CSR and SHM in different ethnic groups. It would also be of interest 
to analyze these associations along with the rate of SHM and CSR 
and extent of radiosensitization. 
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Oral Allergy Syndrome Due to Nut Oleosins
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IgE-mediated reactions to fruits and vegetables are 
common in patients with allergy symptoms caused by pollen. 
Different families of defense, structural, and storage proteins 
have been described as major allergens in pollen-food allergy 
syndrome.
The most serious reactions reported include gastrointestinal, 
skin, eye, respiratory, and cardiovascular symptoms. 
Anaphylactic reactions due to foodstuffs usually occur 
immediately and are diagnosed by skin prick testing, specific 
IgE determination, and, when required, oral provocation.
We report the case of a 55-year old woman who reported 
several episodes of oral pruritus (Grade 0 allergy reaction) after 
eating fried peanuts and raw walnuts and 1 episode of lingual 
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Figure. Immunoblotting with the patient´s serum. Note the bands that 
identify oleosins (18-20 kDa) and probably caleosins (35-37 kDa). MW 
indicates molecular weight; AF, aqueous fraction; OB, oil body fraction.
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angioedema (Grade 2 allergy reaction) after eating oil-fried 
peanuts. The patient did not eat other kinds of nuts and reported 
no problems with other plant foods, only mild symptoms with 
some spices. Symptoms consistent with rhinoconjunctivitis 
had been observed after exposure to dust and seasonally since 
the patient was 20 years old (over 30 years before the onset of 
symptoms with the ingestion of nuts). All the symptoms were 
mild and did not require treatment. 
Skin prick tests were carried out with a full battery of 
foodstuffs including spices and common aeroallergens in our 
setting (ALK Abelló Laboratories). Specific IgE to pollens, 
house dust mites, and nuts was determined, and prick-by-prick 
skin tests were performed with peanuts, walnuts, olive oil, 
and sunflower oil. Serum was obtained for immunoblotting.
Skin prick tests were positive for Dermatophagoides 
pteronyssinus (3 mm), Dermatophagoides farinae (3 mm), 
and grass pollen (3 mm), and negative for the remaining 
aeroallergens and foodstuffs tested, including profilin and 
lipid transfer protein (purified natural date palm profilin and 
commercial peach extract from ALK Abelló). The prick-
by-prick tests for peanuts, walnuts, olive oil, and sunflower 
oil were negative in all cases. Total IgE was 27.5 IU/mL 
and specific IgE was negative for walnuts (0.01 kU/L), 
D pteronyssinus, D farinae (0.01 kU/L), lolium (0.10 kU/L), 
peanuts (0.01 kU/L), and almonds (0.01 kU/L).
Immunoblotting showed bands with a molecular weight 
of 18 to 20 kDa corresponding to the oleosins, and of 35 to 
37 kDa, probably corresponding to the caleosins.
Allergy to nuts is one of the most prevalent allergies 
in our setting. In general, these are sensitivities that trigger 
severe IgE-mediated reactions that can cause moderate 
or severe anaphylaxis. In the case of peanuts, the protein 
fractions identified to date correspond to storage proteins 
(Ara h 1, 2 and 3), lipid transfer protein (Ara h9), and PR10 
(Ara h8) [1].
Recent reports have described new protein fractions, 
called oleosins, which are recognized by IgE antibodies from 
patients sensitized to olives, sesame, and nuts, and which 
cause allergic reactions ranging from oral allergy syndrome 
to anaphylaxis [2,3]. These reports used standard prick tests 
and specific IgE determinations, which provided negative 
results. Although isolated reports have shown sensitization 
to the agents tested using prick-by-prick tests prepared with 
saline, in most cases specific techniques to conserve the lipid 
fractions of the extracts were required. Patch tests were useful 
in these cases, with positive readings just 20 minutes after 
application of the patch. This might be explained by the low 
molecular weight of the sensitizing oleosins.
More recent reports have not only identified oleosins as 
sensitizing lipid fractions (fractions Ara h10 and 11 of peanuts) 
but also establish that these are gastroresistant allergens. This 
might explain the cases of anaphylaxis reported in the literature 
and the existence of cross-reactivity with other plant foods 
such as buckwheat, which has been tested by RAST inhibition 
techniques [4].
In conclusion, we have reported the case of a patient with 
oral pruritus after ingestion of peanuts and walnuts and allergic 
sensitization to oleosins. Skin prick tests, prick-by-prick tests, 
and specific IgE were negative for the suspected foodstuffs. 
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We hypothesize that these negative results might be due to 
the lipid nature of the allergen in question and, therefore, 
the difficulties inherent in its processing. Interestingly, most 
allergenic extracts are obtained by water-soluble methods 
that could eliminate these lipid derivatives of the allergenic 
extract [1]. The role of lipid derivatives in food allergies 
requires deeper investigation. In the present case, we advised 
our patient to strictly avoid all kinds of nuts. Unfortunately, 
she did not want to continue the study with other procedures, 
such as patch testing or further diagnostic procedures.
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A threshold ice cube challenge test, which consists of the 
application of an ice cube on the skin of the right forearm for 
30 seconds, 1, 2, and 5 minutes and measuring the time needed 
to induce skin response [2], resulted in the appearance of a 
large wheal and flare within 2 minutes, despite the fact that 
the patient was being treated with antihistamines.
Complete blood count revealed normal values. The 
biochemical parameters analyzed (glucose, creatinine, urea, 
total proteins, iron, ferritin, C3, and C4) were within normal 
ranges. Aspartate transaminase and alanine transaminase 
were slightly elevated (69.5 and 75.7 respectively), but in 
a subsequent test, they had returned to normal (40.3 and 
19.6 respectively). The erythrocyte sedimentation rate was 
6 mm/h, and the reactive C protein level was 0.02 mg/dL. 
Cold agglutinins were not detectable. 
Anti-tissue transglutaminase IgA titers were within 
the normal range. Total IgE was 14.9 IU/mL. Antibodies 
from hepatitis C, toxoplasmosis, and cytomegalovirus were 
undetectable, as were IgM antibodies to Epstein-Barr virus. 
IgG antibodies to Epstein-Barr virus, however, were positive 
(index 1.01).
The clinical history of the patient’s reactions, the absence 
of systemic illness, the negative results for cryoproteins, and 
the positive ice cube challenge test were consistent with a 
diagnosis of primary cold urticaria [1,2]. We established 
preventive treatment with cetirizine (2.5 mg twice daily) 
and concomitant use of montelukast (4 mg once daily). 
Hydroxyzine syrup was prescribed for mild reactions following 
cold exposure, and the family was instructed in the use of 
injectable epinephrine for episodes involving generalized 
urticaria or systemic symptoms. Despite this treatment, 
however, the patient continued to experience episodes of 
generalized urticaria, and we therefore opted for an empirical 
trial with omalizumab (75 mg every 4 weeks). 
After the sixth injection of omalizumab, we repeated the 
threshold ice cube challenge test and observed no wheals after 
10 minutes of application. In addition, we decided to expose 
the patient to cold water, trying to mimic the conditions that 
had triggered the anaphylactic reaction in the kindergarten 
playground. We covered the patient’s body with cold wet 
Treatment of Severe Cold-Induced Urticaria in a 
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Cold urticaria is typically induced by contact with cold 
water or cold air, and the reaction often occurs on rewarming 
of the exposed area [1,2]. Wanderer et al [3] proposed a 
classification for cold urticaria based on severity of reactions; 
they referred to local reactions in exposed areas of skin 
(type 1), generalized urticaria (type 2), and episodes associated 
with systemic symptoms (type 3). It is important to highlight 
that systemic anaphylactic reactions are common in cold 
urticaria and occur most often during swimming or aquatic 
activities [4], which can result in death. Thus, it is imperative 
that patients with cold-induced urticaria be cautioned against 
swimming, bathing, or similar water activities, and be provided 
with self-injectable epinephrine. 
We describe the case of a 2-year-old boy who presented 
urticarial rashes after exposure to cold temperatures. The first 
episode had occurred at a ski resort when the patient was aged 18 
months. After a few minutes outside, despite being adequately 
dressed for the cold, he developed a widespread urticarial 
rash. After that, the episodes of urticarial rash became more 
frequent in cold winter months and interfered with kindergarten 
attendance. There were no associated constitutional symptoms, 
such as fever or arthralgias. The patient was able to tolerate the 
ingestion of cold liquids and food.
At the age of 23 months, in June, while the patient 
and his classmates were throwing cold water at each other 
in the kindergarten playground, he suddenly experienced 
widespread urticaria, a lack of energy, and a reduced level of 
consciousness for 90 minutes. He improved on arrival at the 
hospital, regaining a normal level of consciousness and with 
all his vital signs within normal ranges. 
His past medical history did not reveal anything significant. 
He was not atopic and had never had asthmatic or rhinitis 
symptoms, dermatitis, or other cutaneous lesions. There was no 
evidence of reactions to different types of food or drugs. He had 
not undergone any blood transfusions, and none of the members 
of his family had ever experienced cold-induced rashes.
Physical examination did not reveal any abnormalities. The 
skin was lesion-free and the lymph nodes were of a normal 
size. The chest was clear to auscultation, the abdomen was 
soft, and there was no organomegaly. 
Figure. Exposure to cold water, in an attempt to mimic the conditions 
that triggered the anaphylactic reaction.
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dressings, while monitoring vital signs. Every few minutes, 
we replaced dressings that were becoming warm with new 
cold dressings. This procedure was continued for 20 minutes 
(Figure, informed consent obtained). When all the dressings 
had been removed, there were only some small erythematous 
areas observable on the hip and left leg; there were no wheals 
and the patient’s vital signs remained stable. 
After 9 months of treatment, the patient started to bathe in 
the family swimming pool, and only developed mild cutaneous 
erythema in a few spots. He could also stay outside during 
cold months without developing lesions in exposed skin areas.
The marked improvement in this patient and in another 
case reported in the literature following treatment with 
omalizumab [5] adds strength to the proposed pathogenetic 
role for IgE in cold-induced mast cell activation in patients 
with cold-induced urticaria [6]. 
This is one of the few cases reported of successful 
response to treatment with omalizumab in severe cold-induced 
urticaria [5,7,8]. We found only 1 case describing this treatment 
in a pediatric patient [5], in which successful treatment of 
cold-induced urticaria-anaphylaxis with omalizumab was 
reported in a 12-year-old girl. In that case, after a few months 
of treatment with omalizumab, exposure to cold air and 
bathing in the sea produced only mild cutaneous pruritus 
and not urticaria, allowing the patient to ski and swim. Our 
patient also improved enormously, and after a few months of 
treatment with omalizumab, was able to do typical activities 
for his age. Both patients had a negative ice cube challenge 
test after treatment with omalizumab.
Studies on other patients with cold-induced urticaria are 
necessary to establish the clinical effectiveness of omalizumab 
observed in these cases.
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presence of 2 or more AR symptoms besides cold, and 
frequency and severity of AR symptoms. Specific questions 
put to patients included “Do you have one or more of these 
symptoms (runny nose, stuffy nose, itchy nose, sneezing, and 
itchy eyes) without having a cold?”, “When you have such 
symptoms how long do they last? (less than 4 days a week for 
less than 1 month or more than 4 days a week for more than 
1 month)”, and “When you have these symptoms, do they 
affect your sleep?”.
Physicians were blinded to the patients’ replies in order 
to ensure objectivity.
The study was conducted between March and December 
2011 throughout Italy and involved 1700 GPs participating in 
a continuing medical education program who were asked to 
enroll a maximum of 5 consecutive asthma patients. 
Continuous variables were expressed as mean (SD). 
Potential associations between patients and GPs’ answers were 
evaluated using the chi-square test.
The k index (9) was used to assess the degree of 
concordance between the patient and the physician in reporting 
the presence and severity of rhinitis. 
Of the 1700 participating physicians, 1678 (98.7%) 
completed the questionnaire and enrolled at least 2 patients 
each. Of the 3950 patients, 3527 (89.3%) signed an informed 
consent form and completed the questionnaire.
Fifty-three patients with an incomplete questionnaire were 
excluded Thus, the analyses were performed on a sample of 
3474 patients (mean age, 48.93 [15.16]; males, 59.5%). 
A total of 1526 patients (44.1%) reported the presence 
of AR. GPs indicated the presence of AR in 2382 patients 
(69.5%). An association was found between patients’ 
perception of disease and physicians’ judgment with respect 
to the presence of rhinitis (chi-square, 133.95; P<.001), but 
the level of concordance was poor (k=0.17).
In 1201 cases, both patients and GPs reported the presence 
of AR, which was defined as persistent by 48.7% of patients 
and 51.6% of physicians. As for persistence of AR, a significant 
association was detected between patient and GP evaluations 
(chi-square, 73.6; P<.001), but concordance was again poor 
(k=0.2).
AR was classified as moderate-severe by 14.4% of patients 
and 43.1% of physicians. A significant association was found 
between patients and GPs with respect to severity (chi-square, 
17.7; P<.00), but concordance remained weak (k=0.4).
Although the ARIA guidelines emphasize the relevance of 
AR and its impact on asthma management, implementation 
of guidelines in clinical practice is often unsatisfactory [5]. 
Difficulties in the application of recommendations could be 
ascribed to several factors, including poor patient–physician 
communication and different perceptions of a clinical 
problem [4]. The present study, which was performed on a 
large population of asthma patients, showed that the level of 
concordance between GPs and their patients with respect to 
AR is poor. As shown in other diseases [10], patient–physician 
concordance makes it possible to share clinical management. 
On the contrary, poor concordance could lead the physician 
to make choices that are not matched to patient’s experience, 
thus leaving the patient with untreated symptoms and exposed 
to potential asthma triggers. 
Do Asthmatic Patients and Their Physicians Agree on 
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Allergic rhinitis (AR) and asthma often coexist. Up to 
80% of asthma patients have AR, and more than 40% of AR 
patients complain of asthma [1]. The links between these 2 
conditions are well characterized, and both likely represent a 
continuum of the same disease.
The Allergic Rhinitis and its Impact on Asthma (ARIA) 
guidelines [2] underline the importance of such links, provide 
recommendations on prevention and treatment, and suggest 
that asthma patients should be evaluated for AR and that all 
AR patients should undergo asthma tests.
Both the severity and the duration of rhinitis symptoms 
are determinants of asthma control [3]. Rhinitis is associated 
with increased unscheduled visits, risk of hospitalization, and 
drug consumption due to asthma [3]. Moreover, irrespective 
of their level of asthma control, patients with rhinitis reported 
worse health-related quality of life scores [4].  
These data support the hypothesis that optimal management 
of AR can improve asthma. A combined treatment strategy 
should be planned in order to achieve the best possible health 
status [2]. 
Despite the availability of evidence-based guidelines, 
recommendations are not fully applied in clinical practice [5], 
with the result that AR often goes undiagnosed [6]. Few AR 
patients seek medical care, because they underestimate their 
disease or self-manage it [2]. 
We hypothesized that patients and physicians could have 
different perceptions of AR. Our hypothesis was verified using 
the database of a recent cross-sectional study that assessed the 
prevalence of obstructive sleep apnea syndrome symptoms in 
a large sample of asthma patients with and without comorbid 
rhinitis [7]. We sought to explore the perception of the presence 
and severity of rhinitis in asthma patients and their physicians.
The full methodology of the study whose database we 
used has been reported elsewhere [7]. Briefly, a quantitative 
questionnaire-based research program was implemented. 
The study population included adult patients with asthma 
diagnosed by their general practitioner (GP) according to the 
Global Initiative for Asthma [8] guidelines. After obtaining 
informed consent, the GPs indicated the presence and the 
classification of AR according to the ARIA guidelines [2] 
on the basis of the clinical features or data from the patient’s 
medical record by ticking a precoded form. 
Patients then completed a questionnaire to provide 
demographic characteristics (age, sex, height, and weight), 
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Our study should be viewed in the light of its limitations. 
The cross-sectional design and the a priori exclusion of 
variables that could affect concordance (eg, time allotted for 
the visit, personal characteristics of the physician and the 
patient) weaken our findings. 
In conclusion, our results highlight the need for further 
interventions aimed at increasing awareness, perception, and 
management of AR, especially in asthma patients. 
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Crizotinib (Xalkori, Pfizer) is an anticancer drug that acts 
as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 
inhibitor. It has proven to be more efficacious than standard 
chemotherapy in advanced ALK-positive non–small cell 
lung cancer (NSCLC), which represents 4-6% of all cases of 
NSCLC [2]. Crizotinib is becoming a first-line treatment in 
patients with NSCLC.
Cutaneous reactions to crizotinib are reported in both 
phase I and phase III trials at a frequency of 11% and 9%, 
respectively, and are vaguely described as cutaneous rashes. 
The only cases of reactions to crizotinib are 1 report of severe 
photosensitivity dermatitis [3] and, more recently, 2 cases in 
which the manifestations were urticaria and maculopapular 
rash, respectively [4]. 
Suitable alternatives to target-specific drugs are not usually 
available. When hypersensitivity reactions do occur, it is 
worth evaluating desensitization [5]. This approach has been 
in use for some time, but in the last few years it has become 
increasingly important with the progressive emergence of 
target-specific therapies [6]. Desensitization consists of the 
administration of increasing doses—usually doubling up—of 
the culprit drug at fixed time intervals of 15-30 minutes, thus 
avoiding mast cell and basophil degranulation [5]. Different 
protocols have been described, especially for antineoplastic 
agents and monoclonal antibodies [6-8], and most are designed 
for intravenous administration. In the case reports described 
above [3,4], application of a 12-step desensitization protocol 
enabled patients to tolerate the drug. Here, we report a new case 
of hypersensitivity reaction in which the patient underwent 
a complete allergy workup and a fast oral desensitization 
protocol.
The patient was a 78-year-old woman (nonsmoker) 
diagnosed with metastatic ALK-positive NSCLC who started 
receiving oral crizotinib 250 mg twice daily in January 2014 
as a third-line treatment. The drug was well tolerated for the 
first 40 days, and the patient only experienced grade II asthenia 
and grade I edema. Four hours after the morning dose, the 
patient presented with itchy hives on the head, chest, and back. 
The reaction improved progressively during the day without 
medication, but 1 hour after intake of the following dose, the 
reaction became more intense, with associated facial edema. 
She was treated with intramuscular dexchlorpheniramine 5 mg 
by her general practitioner, who prescribed oral cetirizine 
10 mg twice daily and advised her to suspend crizotinib. The 
symptoms disappeared 10 hours later. 
The oncologist revisited the patient and assessed the 
efficacy of crizotinib. As a partial response was obtained 
according to the Response Evaluation Criteria in Solid Tumors 
rules [9], the decision was taken to continue with the same 
treatment, and the patient was referred to the allergy unit for 
a workup. On March 25, 2014, the patient was evaluated by 
an allergist. After giving her written informed consent, she 
underwent a skin prick test (SPT) and intradermal tests (IDT) 
with the culprit drug following the European Network for Drug 
Allergy recommendations [10]. Briefly, crizotinib capsules 
were suspended in water for injection at a concentration 
of 25 mg/mL and then diluted to 1:1000. SPT was carried 
out at 25 mg/mL and IDT at 1:1000 and 1:100 of the SPT 
concentration. The results were negative. The results were 
also negative in 5 controls. Drug handling and dilutions were 
carried out at the hospital’s pharmacy for safety reasons. A 
basophil activation test was also performed on fresh whole 
blood using the Flow2CAST kit (Bühlmann). The stimulus 
used was a solution of crizotinib in dimethyl sulfoxide at 
different concentrations (0.05, 0.03, 0.005, 0.003, 0.001, and 
0.0003 mg/mL), but no stimulus was detected at any dose.
As crizotinib was the most efficacious drug for treatment, 
a rapid oral desensitization protocol was proposed. On April 3, 
2014, the patient received intramuscular dexchlorpheniramine 
5 mg and intramuscular methylprednisolone 40 mg 30 minutes 
before starting the desensitization protocol. The oncologist 
established the target dose at 200 mg owing to potential toxicity 
and the patient’s decision. Increasing doses of a suspension of 
crizotinib—prepared in the same way as for the SPT—were 
administered stepwise at intervals of 30 minutes following the 
schedule shown in the Table. A cumulative dose of 200 mg 
was administered over 2 hours. The protocol was designed 
according to our previous experience in oral desensitization 
protocols and risk assessment based on the characteristics 
of the reaction and the tests performed. Vital signs were 
monitored throughout the procedure, and no alterations in heart 
rate or blood pressure were recorded. The patient remained 
under observation at the allergy unit for 2 hours after the last 
dose, and no adverse reactions were observed. 
The patient subsequently continued to receive oral 
crizotinib at 200 mg twice daily. No further adverse reactions 
were reported after more than 7 months of treatment, except 
for asthenia and edema (both grade I). 
In August 2014, the patient complained of lightheadedness 
and vertigo. Cranial nuclear magnetic resonance revealed a 
hyperintense image in the right pontomesencephalic region 
that was compatible with metastasis. As radiosurgery was 
indicated, crizotinib had to be discontinued on October 15, 
2014. On December 11, 2014, crizotinib was reintroduced 
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with the same desensitization schedule, and no adverse events 
were recorded. 
Although we could not demonstrate an IgE-mediated 
mechanism, the onset and characteristics of the reaction point 
to a type I hypersensitivity reaction. Negative skin test results 
are not infrequent in suspected hypersensitivity reactions [6,8], 
even in those where a desensitization protocol is successful; 
therefore, mechanisms other than IgE-mediated mechanisms 
could be involved. Since crizotinib was more efficacious than 
other drugs in the present case, a desensitization procedure 
was the best option. 
A complete allergy workup should be mandatory for this 
kind of reaction, as we need as much information as possible 
to select and tailor treatment. The protocol we applied was 
successful, despite our limited experience. It was also faster 
and shorter than that of Awad et al [4] (2 hours vs 3 hours 
and 5 steps vs 12 steps). The protocol should be tested in 
more patients to confirm its usefulness in the treatment of 
hypersensitivity reactions to crizotinib.
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Table. Crizotinib Desensitization Protocola
Step Dose, mg
1 10
2 15
3 25
4 50
5 100
aDoses were administered every 30 minutes, with a final 
observation period of 120 minutes.
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An 11-year-old boy weighing 26 kg was admitted to 
our hospital with a 4-day history of mucocutaneous purpura 
secondary to immune thrombocytopenia (ITP). Large bruises 
were present on both legs, and petechial lesions were observed 
on his neck. His platelet count was 11 000 platelets/mm3, with 
no red cell or leukocyte abnormalities. Clotting was normal. 
The child had had asthma for several years and was taking 
inhaled fluticasone. He occasionally required oral prednisolone 
or deflazacort combined with inhaled salbutamol to treat 
exacerbations. No adverse reactions to these drugs were noted. 
The patient ate sole 15 minutes before starting treatment 
for ITP with intravenous methylprednisolone hemisuccinate. 
He experienced itching, generalized urticaria, eyelid 
angioedema, and moderate bronchospasm within 3 minutes 
of administration. The infusion of methylprednisolone 
was stopped, and the patient recovered after treatment 
with intramuscular adrenaline (300 µg), intravenous 
dexchlorpheniramine (4 mg), and nebulized salbutamol 
(4 mg). His symptoms resolved after 25 minutes.
We performed a skin prick test (SPT) and an intradermal 
test (IDT) with corticosteroids and an SPT with latex and 
sole. SPT was performed by applying a drop of the test 
solution at full concentration (only SPT could be performed 
for prednisolone because the only formulation available is for 
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oral use). The results of both SPT and IDT were considered 
positive when the wheal reaction was at least 3 mm larger than 
that elicited by the saline control.
The results of SPT using methylprednisolone hemisuccinate 
(10 mg/mL), hydrocortisone (100 mg/mL), prednisolone 
(7 mg/mL), triamcinolone (40 mg/mL), dexamethasone 
(4 mg/mL), budesonide (0.5 mg/mL), betamethasone 
(6 mg/mL), sole, and latex were all negative. The IDT with 
methylprednisolone hemisuccinate at a 1:10 dilution (1 mg/mL) 
was positive (15×15 mm). The results of IDT to the other 
corticosteroids (hydrocortisone, triamcinolone, budesonide, 
dexamethasone, and betamethasone) were negative. SPT and 
IDT to corticosteroids at those concentrations were negative 
in patients who were not allergic to corticosteroids (controls). 
Excipients (monosodium and disodium phosphate) were 
excluded, as the patient had tolerated them in the other drugs.
The result of an oral challenge with prednisolone (25 mg) 
and dexamethasone (12 mg) was negative, as was that of an 
intravenous challenge with hydrocortisone (160 mg). All 
challenges were performed in a hospital setting under medical 
supervision and with intravenous access and the necessary 
medications, personnel, and equipment to treat anaphylactic 
reactions. Challenges were graded using incremental doses 
(1:10, 1:1) every 1 hour. The drugs tested are shown in the 
Table.
Prior to discharge, the patient received oral prednisolone to 
increase his platelet level to 49 000/mm3. He was discharged 
with oral prednisolone (46 mg every 12 hours) for 6 days 
and an epinephrine autoinjector and experienced no further 
adverse reactions.
Although corticosteroids are usually prescribed for 
their antiallergenic effects, immediate hypersensitivity 
reactions, including anaphylactic reactions, and delayed 
allergic reactions, mainly allergic contact dermatitis, have 
been reported [1]. Immediate reactions are less frequent than 
delayed reactions, and their exact incidence is unknown [1]. 
Previously published data show that the conditions associated 
with a greater risk of developing immediate hypersensitivity 
to corticosteroids include renal transplant, rheumatic 
disease, hypersensitivity to nonsteroidal anti-inflammatory 
drugs, and asthma with significant exposure to parenteral 
corticosteroids [1-5]. In the case we report, the patient had 
never received intravenous corticosteroids. Moreover, to our 
knowledge, hematological diseases have never been reported 
Table. Drugs Tested
Drug  Skin Prick Test   Intradermal Test Challenge
Methylprednisolone hemisuccinate 10 mg/mL  0×0 mm 1:10  15×15 mm Not done
Hydrocortisone 100 mg/mL  0×0 mm 1:10  0×0 mm Tolerated
Prednisolone 7 mg/mL  0×0 mm 1:10  0×0 mm Tolerated
Triamcinolone 40 mg/mL  0×0 mm 1:10  0×0 mm Not done
Budesonide 0.5 mg/mL  0×0 mm 1:1  0×0 mm Not done
Dexamethasone 4 mg/mL  0×0 mm 1:10  0×0 mm Tolerated
Betamethasone 6 mg/mL  0×0 mm 1:10  0×0 mm Not done
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to be a risk factor, as in the case we present. The role of the 
immunological disease ITP in the hypersensitivity reaction 
experienced by the patient we describe is unknown. 
Some authors suggest that the corticosteroids most 
commonly involved in immediate hypersensitivity reactions 
are methylprednisolone and hydrocortisone and that the 
reaction results from their affinity for serum proteins [6,7]. 
Others conclude that the most frequently involved drugs 
are oral prednisone and prednisolone, both of which are 
commonly used for outpatient therapy [5]. Information about 
the sensitivity and specificity of SPT and IDT to corticosteroids 
is limited, although sensitivity has been estimated at 86% [5]. 
In vitro tests such as allergen-specific IgE detection with 
corticosteroids and the basophil activation test are difficult to 
perform but can effectively complement skin tests [1]. 
Cross-reactivity between drugs has also been suggested, 
as some patients reacted to more than 1 corticosteroid [5,8]. 
Ventura et al [8] suggested that hydrocortisone is more likely to 
cross-react with methylprednisolone than with dexamethasone 
or betamethasone. The largest available series (15 patients) 
revealed no patterns of cross-reactivity based on the clinical 
history and the results of the skin tests [5]; therefore, systematic 
individualized evaluation of the sensitization/tolerance 
profile is necessary [1]. In the case we report, the patient 
reacted to methylprednisolone hemisuccinate but tolerated 
other corticosteroids including hydrocortisone. Succinate 
ester in particular seems to have immunological potential, 
but the mechanism of action has not yet been clarified [9]. 
As it is impractical to recommend complete avoidance of 
systemic corticosteroids because of their widespread use, it 
is mandatory to offer the patient alternative corticosteroids 
(especially in diseases such as ITP, where corticosteroids are 
a key treatment). A graded drug challenge is usually required 
to confirm tolerability. In this regard, a negative IDT result 
correlates with clinical tolerance in many patients [5,10]. 
Rachid et al [5] described a patient who tolerated 2 courses of 
an alternative corticosteroid and had an anaphylactic reaction 
to the third course. Injectable epinephrine for emergency use 
is recommended in outpatients with corticosteroid allergy 
who are receiving an alternative well-tolerated corticosteroid.
In conclusion, our findings are compatible with 
IgE-mediated anaphylaxis due to methylprednisolone 
hemisuccinate confirmed by IDT. We found no cross-reactivity 
to prednisolone, dexamethasone, or hydrocortisone in the 
context of ITP. Clinicians should not underestimate the 
allergenic potential of corticosteroids and should be aware that 
severe anaphylactic reactions to corticosteroids can even occur 
in individuals with no predisposing conditions. Therefore, 
patients who require high doses of corticosteroids should be 
carefully monitored, regardless of their disease.
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A specific nasobronchial provocation (SNBP) was 
performed with an aqueous extract of T molitor larvae 
(10% wt/vol) using the tidal volume method with a face mask 
covering the nose and mouth as previously described [7]. The 
patient presented intense anterior rhinorrhea 6 minutes after 
the procedure commenced. No significant changes in acoustic 
rhinometry parameters were observed during the 24 hours after 
SNBP; in fact, the maximum fall in minimal cross-sectional 
area in acoustic rhinometry was 13.8% at 20 minutes after 
SNBP. Forced expiratory volume during the first second 
(FEV1) did not change during the 24 hours after SNBP. FEV1 
and peak expiratory flow were monitored using a computerized 
asthma monitor (Amos, Jaeger) every hour except when the 
patient was sleeping. A methacholine challenge test performed 
24 hours after SNBP was negative (PC20 >16 mg/dL), and no 
significant change in FeNO was recorded 24 hours after SNBP 
(11.4 ppb). Baseline nasal cytology revealed few leukocytes 
and no eosinophils, and the post-SNBP cytology revealed 
eosinophils (10%). The patient had not come into contact with 
T molitor larvae in the 2 months before the SNBP, and her 
respiratory symptoms had improved significantly.
A T molitor larvae extract was prepared by homogenization 
in PBS 0.01 M, pH 7.4. Two consecutive extractions were 
made (4 hours at 4ºC and overnight at 4ºC). The content was 
centrifuged and the supernatant collected, dialyzed, filtered, 
frozen, and freeze-dried. Protein content was measured using 
the Lowry-Biuret method (Sigma).
SDS-PAGE with T molitor larvae extract (20 μg protein/
lane) (Figure, A) revealed several protein bands. The most 
abundant bands were observed at 65, 25, 20, and 12 kDa. An 
IgE immunoblotting analysis performed with the patient’s 
serum revealed 4 bands at approximately 65, 40, 35, and 
28 kDa (Figure, B).
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Insect larvae are potent sensitizers in the workplace and 
in other settings [1,2]. Several larvae have been reported 
to be allergenic, including Tenebrio molitor [3], Galleria 
mellonella [4], Calliphora erythrocephala [5], Calliphora 
vomitoria [6], and Lucila caesar.
The life cycle of T molitor consists of 3 stages, namely, 
larva, pupa, and adult. Owing to its high protein content (20%) 
and high lipid and chitin content, the larva of T molitor is used 
as live food for insectivorous pets, fishing bait, and human 
consumption. Humans may be exposed to this larva in the 
workplace or at home.
We report the case of a 54-year-old woman with no 
previous history of atopic disease who presented at the 
outpatient clinic of our hospital with a 4-month history 
of persistent dry cough that tended to worsen during 
the morning and late afternoon. Her condition did not 
improve despite treatment with antitussive drugs. During 
the previous months, the patient had also experienced 
increasingly recurrent episodes of sneezing, nasal itching, 
and rhinorrhea at home with no apparent trigger, although 
she did notice an improvement while she was away 
from home. All of the symptoms were observed outside 
springtime. 
The patient had 7 pet geckos with which she had been in 
close contact for 3 years, feeding them T molitor larvae twice 
a day (morning and afternoon). She did not use a protective 
mask or gloves to feed the animals. 
A physical examination revealed no skin lesions, and 
findings of anterior rhinoscopy and cardiopulmonary 
auscultation were normal. A chest x-ray showed asymmetry 
in the soft tissue, with no other abnormalities. The Mantoux 
test was negative.
Skin prick tests were performed with common inhalants, 
and the only reactions were to olive and grass pollen. 
Prick-by-prick testing was positive for dermal remnants of 
T molitor larvae (4×5 mm) and negative for dermal remnants 
of gecko. Prick testing with aqueous extract of T molitor 
larvae (10% wt/vol) was positive (6×4 mm) in the patient 
but negative in 5 controls, who had never been exposed to T 
molitor. Spirometry results were normal, with no reversibility 
after inhalation of a bronchodilator. The fraction of exhaled 
nitric oxide (FeNO) was 13 ppb. The result of a methacholine 
challenge test was negative (PC20 >16 mg/dL).
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Figure. Protein SDS-PAGE (A) and immunoblot (B) with serum IgE from 
the patient. Twenty micrograms of the lyophilized Tenebrio molitor extract 
was loaded in both cases. For the immunoblot, the serum was used half-
diluted. Molecular weight markers are shown on the left. IgE-binding 
bands are marked with arrows.
65
kDa kDa
A B
97.4
66.2
45.0
31.0
21.5
14.4
40
35
28
Practitioner's Corner
J Investig Allergol Clin Immunol 2015; Vol. 25(4): 295-315 © 2015 Esmon Publicidad
  Manuscript received December 20, 2014; accepted for 
publication February 6, 2015. 
Silvia Uriarte
Fundación Jiménez Díaz
Reyes Católicos Avenue 2
28040 Madrid
Spain
E-mail: sauriarte@fjd.es
We report a case of allergy caused by exposure to T molitor 
larvae in the home. The SNBP showed a positive nasal 
response based on the presence of nasal symptoms during 
the test and the presence of eosinophils (10%) in post-SNBP 
nasal cytology, although according to the criteria of Dordal 
et al [8] (ie, positivity in SNBP defined as a >25% fall in 
minimal cross-sectional area), no significant changes were 
recorded in post-SNBP acoustic rhinometry parameters. We 
report a rare case of IgE-mediated rhinitis due to T molitor 
larvae in a patient exposed at home. We recorded a positive 
nasal response (symptoms and eosinophils in nasal cytology), 
a positive skin prick test result to aqueous extract of T molitor 
larvae, and an IgE immunoblotting result that revealed 4 IgE 
proteins binding to T molitor larvae extract. We also describe 
IgE-binding proteins that have not been described previously. 
In 1990, Schroeckenstein et al [9] described protein bands of 
32 and 52 kDa in a T molitor pupa extract and bands of 22, 
61, and 67 kDa at other stages of this insect. We did not find 
any similarity to the IgE-binding bands reported by our group 
in a patient with allergy to Galleria mellonella larvae (bands 
of 18, 23, 24, 38, 70, 73, and 77 kDa) [10].
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fever at 2 months of age and was referred to Shinshu University 
Hospital 1 week later. Physical examination revealed mild 
hepatomegaly. The white blood cell count was low (1110/mL), 
and severe neutropenia (55/mL) was observed. The lymphocyte 
count was also reduced (666/mL), with marked decreases in 
numbers of CD3+ T cells (133/mL) and CD16+CD56+ NK 
cells (33/mL). The B-cell count was normal (483/mL). Serum 
transaminase levels were high (aspartate aminotransferase, 
313 [22-64] IU/L; and alanine aminotransferase, 406 [13-55] 
IU/L), as were lactate dehydrogenase levels (649 [203-410] 
IU/L). The patients also had hypogammaglobulinemia 
(IgG, 289 [290-960] mg/dL; IgA, 2 [0-28] mg/dL; and 
IgM, 6 [26-112] mg/dL). CT of the chest revealed a absent 
thymus. Cultures of blood, sputum, throat swab, and urine 
were negative. Cytomegalovirus (CMV) antigenemia was 
detected. Administration of ganciclovir and foscarnet led to 
an improvement in liver function. One week later, the values 
of neutrophils and CD16+CD56+ NK cells had risen to 1675/mL 
and 276/mL, respectively. However, CMV antigenemia was 
not completely negative.
Flow cytometry revealed that expression of CD132 on 
peripheral blood CD19+CD20+ B cells was remarkably less 
intense in cases 1 and 2 than in healthy controls (Figure, A). 
CD132 expression in CD4+ and CD8+ T cells was markedly 
elevated in patient 1, yet apparently normal in patient 2. 
However, expression of CD132 on CD56+ NK cells in case 
2 was low. Fluorescence in situ hybridization analysis of the 
X and Y chromosomes of bead-selected CD3 lymphocytes 
revealed 46XX chromosomes, showing that the T cells were 
maternally engrafted for both cases, whereas 98% of CD56+ 
NK cells in patient 2 expressed XY signals, indicating that 
they were of patient origin.
In patient 1, amplification and sequencing of the coding 
region of the IL2RG gene using reverse-transcriptase 
polymerase chain reaction (RT-PCR) revealed a nonsense 
mutation at the 3' end of exon 2 (c. 269 G>A, p. Trp90X). 
Electrophoresis of the RT-PCR product using primers spanning 
exons 1 through 8 revealed a faint, short mRNA band and 
a faint, normal-sized band (Figure, B). No bands from the 
patient’s mRNA were detected with primers for exons 2 and 
3. We therefore considered that the faint, normal-sized band 
could be traced back to maternal T cells. Sequence analysis 
of the patient’s mRNA revealed that exon 2 (c. 208 to 361) 
had been skipped (Figure, B), thus suggesting markedly 
reduced expression of IL2RG mRNA associated with exon 
2 skipping. Meanwhile, patient 2 had a single base deletion 
at exon 3 (c. 359delA) that resulted in a frameshift mutation. 
This pathological variant of p. Lys120ArgfsX26 has not been 
previously described.
Both patients underwent unrelated cord blood cell 
transplantation after conditioning with thymoglobulin, 
fludarabine, and melphalan. Patient 1 achieved immunological 
reconstitution and successful clinical recovery. Patient 2 
achieved reconstitution of the immune system but developed 
CMV encephalitis 1 month after cord blood cell transplantation 
that caused a mobility disorder of the lower limbs.
We report 2 infants with X-linked SCID and mutations 
that caused stop or exon skipping in the IL2RG gene. A 
Trp90X mutation caused a T–B+NK– phenotype, whereas 
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Severe combined immunodeficiency (SCID) comprises a 
genetically heterogeneous group of primary immunodeficiency 
disorders [1]. Mutations in the IL2RG gene encoding the 
common g chain of the interleukin-2 receptor (CD132) are 
found exclusively in X-linked SCID, which accounts for a 
half of all SCID cases, and result in a lack of both T and NK 
cells (T–B+NK– phenotype) in most patients [2]. CD132 is a 
type I transmembrane glycoprotein that serves as a subunit 
for many cytokine receptors, including IL-2, IL-4, IL-7, IL-9, 
IL-15, and IL-21 [3,4]. The present study describes 2 types 
of mutations detected in the IL2RG gene of 2 Asian male 
infants with SCID: a novel missense mutation in exon 3 and 
a nonsense mutation in exon 2. Although the latter is listed at 
the National Human Genome Research Institute (http:// www.
research.nhgri.nih.gov/scid/), its clinical phenotype has not 
yet been reported. 
Patient 1 was a 6-month-old Japanese male firstborn who 
was delivered normally following an uneventful pregnancy 
at 36 weeks of gestation to a nonconsanguineous couple. 
There was no family history of immunodeficiency. At 2 weeks of 
age, the patient was found to have white plaques on his palate and 
was diagnosed with oropharyngeal candidiasis. At 5 months, he 
experienced recurrent fever with cough and was admitted to Shinshu 
University Hospital, Nagano, Japan for treatment. On admission, 
his white blood cell count was 3980/mL (neutrophils, 1910/mL; 
and lymphocytes, 1234/mL). Flow cytometry revealed decreased 
numbers of CD3+ T cells (99/mL) and CD16+CD56+ NK cells 
(24/mL) but a normal B-cell count (1098/mL). Serum IgG, IgA, 
and IgM levels were low (26 mg/dL [normal range for age, 
290-950 mg/dL], 1 mg/dL [8-50 mg/dL], and 4 mg/dL [46-
176 mg/dL], respectively). Computed tomography (CT) of the 
chest revealed a absent thymus and an extensive ground-glass 
pattern in all lung fields.  
Patient 2 was a 2-month-old male firstborn who was 
delivered at full term to a nonconsanguineous couple of 
Chinese origin. Three of his maternal uncles had died of 
unknown causes during infancy. The patient experienced high 
313
Practitioner's Corner
J Investig Allergol Clin Immunol 2015; Vol. 25(4): 295-315 © 2015 Esmon Publicidad
the novel mutation Lys120ArgfsX26 resulted in a T–B+NK+ 
phenotype. SCID patients with near normal numbers of NK 
cells have been reported [5]. Although most T–B+NK+ SCID 
cases are caused by a deficiency in the interleukin-7 receptor 
a chain, an IL2RG deficiency may also be involved. Patient 
2 was diagnosed as having X-linked SCID during the first 
infection of his life and underwent hematopoietic stem cell 
transplantation. However, he later experienced neurological 
complications due to CMV encephalitis. Neonatal screening 
of T-cell receptor excision is useful for detecting patients with 
SCID, and screening programs have been established in the 
United States and Europe [6,7]. Early diagnosis by means of 
such a screening test at birth, before infection, will improve 
the prognosis and quality of life of SCID patients.
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Figure. A, Surface interleukin 2 receptor g (IL2RG) expression on CD19+CD20+ B cells, CD4+ T cells, CD8+ T cells, and CD2+CD56+ NK cells of patients 
(shaded areas) and healthy controls (outlined areas). Cells were incubated with anti-IL2RG (CD132)-PE and surface markers for each lineage and analyzed 
using flow cytometry. B, Reverse-transcriptase polymerase chain reaction (RT-PCR) analysis of IL2RG mRNA using primers spanning exon 1 to exon 8 or 
exon 2 and exon 3 primer pairs of case 1 and a healthy control. Electrophoresis of the RT-PCR product from primers spanning exon 1 to exon 8 revealed 
a faint short-length mRNA band (arrow). Cont indicates control; Ex, exon.
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